Table 2.
Cox proportional hazards regression for overall survival in patients with esophageal squamous cell carcinoma
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (>65 vs ≤65) | 1.191 (0.851‐1.668) | .309 | – | – |
| Sex (male vs female) | 0.705 (0.386‐1.287) | .255 | – | – |
| Tumor stage (T1‐2 vs T3‐4) | 0.557 (0.249‐1.248) | .155 | – | – |
| LN status (N0 vs N+) | 0.255 (0.123‐0.527) | .001 | 0.238 (0.083‐0.682) | .008 |
| Tumor length (>5 vs ≤5) | 1.576 (0.528‐4.702) | .415 | – | – |
| KPS score (≥80 vs <80) | 0.960 (0.917‐1.006) | .085 | – | – |
| Radiation dose (≤50.4 Gy vs >50.4 Gy) | 1.056 (0.381‐2.925) | .917 | – | – |
| Chemotherapy (PF vs PP) | 0.767 (0.410‐1.435) | .407 | – | – |
| Comorbidities (≥1 vs 0) | 1.634 (0.849‐3.145) | .141 | – | – |
| Weight loss, % (>5% vs ≤5%) | 0.656 (0.336‐1.283) | .218 | – | – |
| VCP expression (high vs low) | 0.457 (0.265‐0.789) | .005 | 2.042 (1.151‐3.621) | .015 |
Abbreviations: –, not included; CI, confidence interval; HR, hazard ratio; KPS, Karnofsky performance status; LN, lymph node; PF, cisplatin + 5‐fluorouracil; PP, cisplatin + paclitaxel; VCP, valosin‐containing protein.